Opportunities and limitations of genomics for diagnosing bedaquiline-resistant tuberculosis: a systematic review and individual isolate meta-analysis-Reference-Cited by-同舟云学术

Opportunities and limitations of genomics for diagnosing bedaquiline-resistant tuberculosis: a systematic review and individual isolate meta-analysis

Published:2024-02 Issue:2 Volume:5 Page:e164-e172
ISSN:2666-5247
Container-title:The Lancet Microbe
language:en
Short-container-title:The Lancet Microbe

Author:

Nimmo Camus^ORCID,Bionghi Neda,Cummings Matthew J,Perumal Rubeshan,Hopson Madeleine,Al Jubaer Shamim,Naidoo Kogieleum,Wolf Allison,Mathema Barun^ORCID,Larsen Michelle H,O’Donnell Max

Funder

Medical Research Council

National Institutes of Health

Cancer Research UK

National Institute of Allergy and Infectious Diseases

Academy of Medical Sciences

National Institute of Allergy and Infectious Diseases Division of Intramural Research

Francis Crick Institute

Wellcome Trust

Publisher

Elsevier BV

Reference22 articles.

1. Consolidated guidelines on tuberculosis. Module 4: treatment—drug-resistant tuberculosis treatment, 2022 update,2022

2. Treatment strategy for rifampin-susceptible tuberculosis;Paton;N Engl J Med,2023

3. Rates and mechanisms of resistance development in Mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor;Huitric;Antimicrob Agents Chemother,2010

4. Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis;Hartkoorn;Antimicrob Agents Chemother,2014

5. Genetic variants and their association with phenotypic resistance to bedaquiline in Mycobacterium tuberculosis: a systematic review and individual isolate data analysis;Ismail;Lancet Microbe,2021

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The epidemiology, transmission, diagnosis, and management of drug-resistant tuberculosis—lessons from the South African experience;The Lancet Infectious Diseases;2024-09